Research never stops


Mar 08, 2018

Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform

Hamburg, Germany; Paris, France, 08 March 2018: Evotec AG and Sanofi have entered into exclusive negotiations for Evotec to accelerate infectious disease research and development through a new open innovation platform near Lyon, France.

- read more
Mar 07, 2018

Evotec to attend upcoming investor conferences

Hamburg, Germany, 07 March 2018: Evotec AG announced today that its management will be presenting at the 24th Prior Kapitalmarktkonferenz, Frankfurt, Germany, and at the H.C. Wainwright Global Life Sciences Conference, Monte Carlo, Monaco, and will be attending the Bankhaus Lampe Deutschlandkonferenz, Baden-Baden, Germany, and the 11th Kempen & Co Life Sciences Conference, Amsterdam, The Netherlands.

- read more
Mar 08, 2018

Webcast/Conference call regarding the exclusive talks with Sanofi

Hamburg, Germany, 08 March 2018: Evotec invites you to join a brief conference call on 08 March 2018 at 02.00 pm CEST. The conference will be held in English.

Please click here for the webcast

Please click here to view the presentation

- read more
Feb 28, 2018

Novo Holdings announce Launch of "REPAIR" and formation of scientific selection board

  • REPAIR, an $ 165 m impact fund to compat antimicrobial resistance to invest in Research and early-stage development
  • Lloyd Payne, EVP Anti-infectives from Evotec will join the scientific selection Board of REPAIR
- read more
Feb 15, 2018

Evotec and MaRS Innovation announce first funded project under LAB150 BRIDGE

Hamburg, Germany, and Toronto, Canada, 15 February 2018:
Evotec AG and MaRS Innovation announced today that they have identified the first project to be developed under their LAB150 partnership.

- read more
Jan 08, 2018

Evotec and APEIRON achieve first milestone in immuno-oncology alliance with Sanofi

Hamburg, Germany and Vienna, Austria, 08 January 2018:
Evotec AG and APEIRON Biologics AG, a company focused on cancer immunotherapy, announced today that the companies received the first milestone payment

- read more